Study of lonitoclax for returning B-cell blood cancers
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of B-cell cancer, like CLL, SLL, or certain lymphomas, that has returned or not responded to treatment.
- You have tried at least 1 or 2 prior therapies, depending on your specific cancer type.
- Your blood cell counts and organ function meet minimum levels (checked through blood tests).
- You are able to perform daily activities with some help (ECOG score 0-2).
- If you could become pregnant or father a child, you agree to use effective birth control during and for 90 days after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (zanubrutinib and sonrotoclax) as a first treatment for people with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). It aims to see if this approach works better than standard care by using a test called MRD to guide treatment duration.
This trial tests two targeted drugs: zanubrutinib followed by a combination with sonrotoclax for people with newly diagnosed CLL or SLL who need treatment for the first time. The goal is to see if a limited-duration, fixed-course treatment can control the disease effectively.
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
This trial tests a new drug called lacutoclax (LP-108) in patients whose chronic lymphocytic leukemia or small lymphocytic lymphoma has stopped responding to previous treatments. The drug is designed to work differently than prior therapies and may help patients whose cancer has come back or become resistant to standard care.
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
This trial tests two oral targeted drugs (BGB-16673 and sonrotoclax) for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have not had treatment before. The goal is to see if this combination is safe and effective.
Hear when a new CLL/SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.